title: Renal function-based contrast dosing predicts acute kidney injury following transcatheter aortic valve implantation.
abstract: OBJECTIVE
  This study sought to assess whether the volume of contrast media (CM) influences the occurrence of acute kidney injury (AKI) following transcatheter aortic valve implantation (TAVI).
  
  
  BACKGROUND
  The volume of CM has been shown to be associated with increasing risk of AKI; however, in a high-risk elderly TAVI population, the predictive value and optimal threshold of CM dose on AKI remain uncertain.
  
  
  METHODS
  Data of 415 consecutive transfemoral TAVI patients (age 83.6 ± 6.8 years, logistic EuroSCORE 23.0 ± 12.2%) were analyzed. AKI was defined by Valve Academic Research Consortium criteria. Based on a previous formula, the ratio of CM to serum creatinine (SCr) and body weight (BW) (CM × SCr/BW) was calculated as defining the degree of CM use. The association between CM dose and incidence of AKI, as well as predictive factors and prognosis of AKI, were investigated.
  
  
  RESULTS
  AKI occurred in 63 patients (15.2%). Cumulative 1-year mortality showed significant differences between the AKI and non-AKI groups (47.9% vs. 15.7%, p < 0.001). Mean CM × SCr/BW ratio was higher in the AKI group than in the non-AKI group (4.1 ± 2.9 vs. 2.9 ± 1.6, p < 0.001). By multivariate analysis, CM × SCr/BW per 1.0 increase, ejection fraction <40%, and transfusion were associated with the occurrence of AKI (odds ratio [OR]: 1.16; 95% confidence interval [CI]: 1.03 to 1.20; p = 0.017, OR: 3.01; 95% CI: 1.49 to 5.00; p = 0.001, OR: 2.73; 95% CI: 1.54 to 6.15; p = 0.001, respectively). A threshold value of CM × SCr/BW for predicting AKI was statistically identified as 2.7.
  
  
  CONCLUSIONS
  Although mechanisms of AKI following TAVI are multifactorial, the present study identified a relationship between CM dose increment and high prevalence of AKI. Therapeutic efforts not to exceed the threshold value may reduce the risk of AKI.
authors.affiliation: Department of Interventional Cardiology, AP-HP, Henri Mondor University Hospital, Créteil, France.
authors.forename: Masanori
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Kentaro
authors.initials: K
authors.lastname: Hayashida
authors.forename: Gauthier
authors.initials: G
authors.lastname: Mouillet
authors.forename: Bernard
authors.initials: B
authors.lastname: Chevalier
authors.forename: Kentaro
authors.initials: K
authors.lastname: Meguro
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Dubois-Rande
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Morice
authors.forename: Thierry
authors.initials: T
authors.lastname: Lefèvre
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Teiger
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced* / Q000401:mortality; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001835:Body Weight; D006328:Cardiac Catheterization / Q000009:adverse effects* / Q000401:mortality; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005602:France / Q000453:epidemiology; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects* / Q000379:methods / Q000401:mortality; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D016017:Odds Ratio; D015995:Prevalence; D011446:Prospective Studies; D015641:Radiography, Interventional / Q000009:adverse effects* / Q000401:mortality; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D003287:Contrast Media; D003404:Creatinine